An investigational antibody could reduce the toxicity associated with immune suppression in islet cell transplantation for type 1 diabetes (T1D), according to new preliminary data. Six people with T1D ...
While Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) has gained 125.83% year-to-date, analysts continue to see 134.60% upside, helping it secure a spot on our list of the hot biotech stocks under $5 to ...
GADA and IA-2A were negative (n = 22) or at low titer (n = 10) in all but 1 of the 33 patients who underwent islet and kidney transplantation. No relationship between the detection of GADA or IA-2A at ...
Century Therapeutics (IPSC) downgraded to Hold after CNTY-101 halted and slow clinical progress. Click here to read my most ...
("Eledon") (NASDAQ: ELDN) today announced updated results from an investigator-initiated trial evaluating tegoprubart, its investigational anti-CD40L antibody, as part of a calcineurin inhibitor-free ...
A combination blood stem cell and pancreatic islet cell transplant from an immunologically mismatched donor completely prevented or cured Type 1 diabetes in mice in a study by Stanford Medicine ...
Add Yahoo as a preferred source to see more of our stories on Google. For Dr. Daniel Gilada, a husband, physician and soon-to-be father of four, living with Type 1 diabetes had become “overwhelming.” ...
NewcelX Ltd. (“NewcelX”; Nasdaq: NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, announced the successful completion of its Type B Pre-IND meeting with ...
A combination blood stem cell and pancreatic islet cell transplant from an immunologically mismatched donor completely prevented or cured Type 1 diabetes in mice in a study by Stanford Medicine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results